Mekinist (trametinib tablets and oral solution – Novartis) — Cigna

Initial criteria

• Patient has not been previously treated with a BRAF inhibitor therapy; AND
• The medication will be used for relapsed/refractory disease; AND
• The medication will be taken in combination with Tafinlar (dabrafenib capsules or tablets for oral suspension).

Approval duration

1 year